Estrogen regulation of angiotensin-converting enzyme mRNA
Estrogen regulation of angiotensin-converting enzyme mRNA
复制标题
DOI：
10.1161/01.hyp.33.1.323
复制
发表时间：
1999-01-01
期刊：
影响因子：
8.3
通讯作者：
Brosnihan, KB
中科院分区：
文献类型：
--
作者：
Gallagher, PE;Li, P;Brosnihan, KB
雌激素替代疗法对绝经后妇女具有心脏保护作用；然而，这种调节的确切分子机制尚未完全阐明。我们先前发现，慢性雌激素替代治疗降低了组织提取物和血清中血管紧张素转换酶(ACE)的活性，并伴随着血浆血管紧张素II的降低，建立了逆转录-聚合酶链式反应方法来确定雌激素治疗是否调节组织ACE mRNA的浓度。用17β-雌二醇替代治疗(每只大鼠SC 5 mg颗粒)或安慰剂治疗21天后，从去卵巢SD大鼠的肾皮质、肾髓质、肺和主动脉提取总RNA。与雌二醇组相比，安慰剂组大鼠所有组织中扩增的ACE基因与延伸因子-1α对照基因的密度比显著降低(肾皮质：0.29+/-0.04比0.14+/-0.02；肾髓质：0.37+/-0.04比0.24+/-0.03；肺：4.49+/-0.37比2.49+/-0.59；主动脉：0.41+/-0.04比0.29+/-0.02；均P
Estrogen replacement therapy is cardioprotective in postmenopausal women; however, the precise molecular mechanisms for this modulation are not fully elucidated. We previously showed that chronic estrogen replacement therapy reduced angiotensin-converting enzyme (ACE) activity in tissue extracts and serum with an associated reduction in plasma angiotensin II, A reverse transcriptase-polymerase chain reaction assay was developed to determine whether estrogen treatment regulates tissue ACE mRNA concentration. Total RNA was isolated from kidney cortex, kidney medulla, lung, and aorta of ovariectomized Sprague-Dawley rats after 21 days of chronic 17 beta-estradiol replacement therapy (5 mg pellet per rat SC) or placebo. A marked decrease in densitometric intensity ratios of amplified ACE cDNA to elongation factor-1 alpha control cDNA was observed in all tissues from placebo-treated rats compared with the estradiol-treated rats (renal cortex: 0.29+/-0.04 versus 0.14+/-0.02; renal medulla: 0.37+/-0.04 versus 0.24+/-0.03; lung: 4.49+/-0.37 versus 2.49+/-0.59; and aorta: 0.41+/-0.04 versus 0.29+/-0.02; all P